Active Ingredient History

  • Now
Levomilnacipran (1S, 2R/F2695) is an enantiomer of milnacipran, a serotonin/norepinephrine (5-HT/NE) reuptake inhibitor. Levomilnacipran is pharmacologically more active as compared with racemic mixture and dextromilnacipran (1R, 2S/F2696). The safety of the drug is also higher than the safety of a racemate, resulting in a beneficial impact on the therapeutic effect. Pierre Fabre and Forest Laboratories are developing levomilnacipran extended release (ER) [FETZIMA™], an enantiomer of milnacipran, for the treatment of major depressive disorder (MDD). In addition, Pierre Fabre (the originator of the compound) is developing the drug to improve recovery in patients with ischaemic stroke.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$9.6717 - $13.8395
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(1s,2r)-milnacipran | f2695 | f-2695 | fetzima | levomilnacipran | levomilnacipran hcl | levomilnacipran hydrochloride


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue